Somerville, United States
Cellarity, launched by Flagship Pioneering in 2017, is a pioneering force in the biotechnology sector. Their slogan, "Rewriting the rules of drug creation," reflects their groundbreaking approach to pharmaceutical innovation by addressing cellular dysfunction rather than focusing on single targets. This strategy helps overcome the limitations of traditional drug discovery in unlocking complex disease mechanisms.
The company's unique methodology leverages proprietary AI models trained on more than 30 million single-cell transcriptomes, offering insights into the biology of diseases. Cellarity is making strides in various therapeutic areas, including metabolic disease, hematology, and immuno-oncology, enhancing their market potential across diverse medical needs.
Headquartered in the United States, their recent financial boost was a $121.00M Series C round completed on 01 October 2022 with backing from notable investors such as BlackRock, Flagship Pioneering, Baupost Group, Hanwha Impact Partners, Kyowa Kirin Co., and Pictet. This investment underscores a strong confidence in their disruptive potential within the biotechnology landscape.
OmicScouts